sorafenib has been researched along with n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide) | Trials (n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide) | Recent Studies (post-2010) (n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 9 | 0 | 9 |
| Protein | Taxonomy | sorafenib (IC50) | n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide (IC50) |
|---|---|---|---|
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 5.9 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 5.9 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 5.9 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 5.9 | |
| Protein-arginine deiminase type-4 | Homo sapiens (human) | 5.9 | |
| Histamine H3 receptor | Homo sapiens (human) | 5.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhiman, N; Jaitak, V; Kaur, K | 1 |
1 review(s) available for sorafenib and n-alpha-benzoyl-n5-(2-chloro-1-iminoethyl)-l-ornithine amide
| Article | Year |
|---|---|
Tetrazoles as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tetrazoles | 2020 |